|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||67.21 - 68.42|
|52 Week Range||50.35 - 72.58|
|PE Ratio (TTM)||53.12|
|Earnings Date||Apr 24, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||0.64 (0.95%)|
|1y Target Est||75.56|
Baxter International Inc (NYSE:BAX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.
Stock Monitor: iRhythm Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free earnings report on Baxter International Inc. (NYSE: ...
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Timken ...
Baxter International Inc. today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.
Baxter International Inc. will present at the Barclays Global Healthcare Conference on Tuesday, March 13, 2018, in Miami, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:15 a.m.
What Can Investors Expect from Becton Dickinson in Fiscal 2018? Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release. BD expects to register adjusted diluted EPS (earnings per share) of $10.85 to $11, which represents YoY (year-over-year) growth of 15% to 16%.
What Can Investors Expect from Becton Dickinson in Fiscal 2018? Becton Dickinson (BDX) released its 1Q18 earnings results on February 6, 2018. For detailed information on the earnings results, read Becton Dickinson’s Fiscal 1Q18 Results Beat Analyst Estimates.
Baxter International Inc. will present at the Raymond James & Associates 39th Annual Institutional Investors Conference on Tuesday, March 6, 2018, in Orlando, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 4:35 p.m.
What's Next for Abbott Laboratories after a Stellar 2017?The impact of 4Q17 earnings release on ABT’s stock price performance
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Baxter International Inc (NYSE:BAX) as an investment opportunity. If youRead More...
Baxter International Inc on Thursday forecast 2018 earnings largely ahead of analysts' estimates and said it would continue to be active on the acquistion front and repurchase more shares through the year. "Any stock which had a guidance coming in-line or below has (seen) a negative reaction," Evercore ISI analyst Vijay Kumar told Reuters, adding that the same had happened to Intuitive Surgical Inc and Illumina Inc in January.
The Deerfield, Illinois-based company said it had a loss of 13 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 64 cents per share. The results ...
Baxter International Inc reported quarterly loss versus year-ago profit as the hospital products maker took a charge of $354 million due to changes in the U.S. tax law. Baxter posted net loss of $71 million, ...